A more pronounced increase of CD8+ T cell frequency (Figure 7H and Supplemental Figure 6D) along with a higher percentage of IFN-γ+ T cells among CD8+ T cells (Figure 7I) was also observed in the prostate tumors following 2-D08 plus anti–PD-1 treatment. This evidence concerns the gene CD8A and prostate neoplasm.